FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245135890> ?p ?o ?g. }

• W4245135890 endingPage "363" @default.
• W4245135890 startingPage "363" @default.
• W4245135890 abstract "363 Background: Immune checkpoint inhibitor (CPI) efficacy has not been established in extrapulmonary poorly-differentiated neuroendocrine carcinomas (EP-PDNECs). In small cell lung cancer, promising antitumor activity of CPI led to accelerated approval of nivolumab in 8/2018. We investigated the efficacy and safety of pembrolizumab (PEM)-based therapy in biomarker-unselected EP-PDNECs. Methods: Open label, multicenter, phase 2 study of PEM-based therapy in patients (pts) with EP-PDNECs, excluding Merkel cell carcinoma and well differentiated grade 3 NET, with progression on first-line systemic therapy, ECOG 0-1, and adequate hepatic and renal function. Enrollment via an adaptive Simon’s 2-stage design. Plan for 14 pts treated with PEM alone (Part A Stage 1) 200 mg IV every 3 weeks. If > 2 of 14 pts respond by week 18, then 21 additional pts enroll in Part A Stage 2, corresponding to H 0 10% vs. H 1 26% response rate (RR) at type I error 0.05 with power 80%. Otherwise study proceeds to Part B: PEM plus chemotherapy (dealer's choice of weekly irinotecan or paclitaxel). Primary endpoint is objective RR (ORR) by RECIST 1.1. Secondary endpoints include safety, overall survival, and progression-free survival (PFS). Serial blood samples and baseline tumor biopsies required in all pts for future biomarker studies. Results: Preliminary data from Part A Stage 1 are available. Of 14 pts enrolled, male/female 9/5; median age 63; 1 large cell, 11 small cell, 2 NOS. Primary site of disease: GI 43%, GU 29%, and other 29%. Median Ki67 80% (available for 9 pts). Best response: CR (1), PR (0), SD (2), PD (10), unevaluable (1; early death from sepsis) for ORR 7%. Median PFS was 58 days. Six (43%) pts went off study for early PD or clinical deterioration before first scheduled scan at 9 weeks. PEM was well tolerated with no grade 3-5 AEs attributed to therapy. At last follow up, 9 (64%) pts were alive with 1 pt still on treatment after 19 cycles. Conclusions: PEM monotherapy was not effective in this pretreated, biomarker-unselected population of EP-PDNECs arising in different organs. Part B (PEM plus chemotherapy) enrollment is ongoing. Biomarker studies are planned (Parts A/B). Clinical trial information: NCT03136055." @default.
• W4245135890 created "2022-05-12" @default.
• W4245135890 creator A5004633925 @default.
• W4245135890 creator A5009409407 @default.
• W4245135890 creator A5027172182 @default.
• W4245135890 creator A5033960518 @default.
• W4245135890 creator A5040007547 @default.
• W4245135890 creator A5043192565 @default.
• W4245135890 creator A5047439875 @default.
• W4245135890 creator A5049619428 @default.
• W4245135890 creator A5059663376 @default.
• W4245135890 creator A5059768717 @default.
• W4245135890 creator A5066716873 @default.
• W4245135890 creator A5072458448 @default.
• W4245135890 creator A5072727753 @default.
• W4245135890 creator A5073970384 @default.
• W4245135890 creator A5079381108 @default.
• W4245135890 creator A5081123075 @default.
• W4245135890 creator A5083373965 @default.
• W4245135890 date "2019-02-01" @default.
• W4245135890 modified "2023-09-28" @default.
• W4245135890 title "Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone)." @default.
• W4245135890 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.363" @default.
• W4245135890 hasPublicationYear "2019" @default.
• W4245135890 type Work @default.
• W4245135890 citedByCount "22" @default.
• W4245135890 countsByYear W42451358902019 @default.
• W4245135890 countsByYear W42451358902020 @default.
• W4245135890 countsByYear W42451358902021 @default.
• W4245135890 countsByYear W42451358902022 @default.
• W4245135890 countsByYear W42451358902023 @default.
• W4245135890 crossrefType "journal-article" @default.
• W4245135890 hasAuthorship W4245135890A5004633925 @default.
• W4245135890 hasAuthorship W4245135890A5009409407 @default.
• W4245135890 hasAuthorship W4245135890A5027172182 @default.
• W4245135890 hasAuthorship W4245135890A5033960518 @default.
• W4245135890 hasAuthorship W4245135890A5040007547 @default.
• W4245135890 hasAuthorship W4245135890A5043192565 @default.
• W4245135890 hasAuthorship W4245135890A5047439875 @default.
• W4245135890 hasAuthorship W4245135890A5049619428 @default.
• W4245135890 hasAuthorship W4245135890A5059663376 @default.
• W4245135890 hasAuthorship W4245135890A5059768717 @default.
• W4245135890 hasAuthorship W4245135890A5066716873 @default.
• W4245135890 hasAuthorship W4245135890A5072458448 @default.
• W4245135890 hasAuthorship W4245135890A5072727753 @default.
• W4245135890 hasAuthorship W4245135890A5073970384 @default.
• W4245135890 hasAuthorship W4245135890A5079381108 @default.
• W4245135890 hasAuthorship W4245135890A5081123075 @default.
• W4245135890 hasAuthorship W4245135890A5083373965 @default.
• W4245135890 hasConcept C121608353 @default.
• W4245135890 hasConcept C126322002 @default.
• W4245135890 hasConcept C143998085 @default.
• W4245135890 hasConcept C203092338 @default.
• W4245135890 hasConcept C2776694085 @default.
• W4245135890 hasConcept C2777546739 @default.
• W4245135890 hasConcept C2777701055 @default.
• W4245135890 hasConcept C2778342957 @default.
• W4245135890 hasConcept C2779984678 @default.
• W4245135890 hasConcept C2780030458 @default.
• W4245135890 hasConcept C2780057760 @default.
• W4245135890 hasConcept C2780739268 @default.
• W4245135890 hasConcept C31760486 @default.
• W4245135890 hasConcept C535046627 @default.
• W4245135890 hasConcept C71924100 @default.
• W4245135890 hasConceptScore W4245135890C121608353 @default.
• W4245135890 hasConceptScore W4245135890C126322002 @default.
• W4245135890 hasConceptScore W4245135890C143998085 @default.
• W4245135890 hasConceptScore W4245135890C203092338 @default.
• W4245135890 hasConceptScore W4245135890C2776694085 @default.
• W4245135890 hasConceptScore W4245135890C2777546739 @default.
• W4245135890 hasConceptScore W4245135890C2777701055 @default.
• W4245135890 hasConceptScore W4245135890C2778342957 @default.
• W4245135890 hasConceptScore W4245135890C2779984678 @default.
• W4245135890 hasConceptScore W4245135890C2780030458 @default.
• W4245135890 hasConceptScore W4245135890C2780057760 @default.
• W4245135890 hasConceptScore W4245135890C2780739268 @default.
• W4245135890 hasConceptScore W4245135890C31760486 @default.
• W4245135890 hasConceptScore W4245135890C535046627 @default.
• W4245135890 hasConceptScore W4245135890C71924100 @default.
• W4245135890 hasIssue "4_suppl" @default.
• W4245135890 hasLocation W42451358901 @default.
• W4245135890 hasOpenAccess W4245135890 @default.
• W4245135890 hasPrimaryLocation W42451358901 @default.
• W4245135890 hasRelatedWork W2799275431 @default.
• W4245135890 hasRelatedWork W2948845624 @default.
• W4245135890 hasRelatedWork W2978259179 @default.
• W4245135890 hasRelatedWork W3034884095 @default.
• W4245135890 hasRelatedWork W3135426710 @default.
• W4245135890 hasRelatedWork W3177224496 @default.
• W4245135890 hasRelatedWork W4206933627 @default.
• W4245135890 hasRelatedWork W4245135890 @default.
• W4245135890 hasRelatedWork W4281648276 @default.
• W4245135890 hasRelatedWork W4296634783 @default.
• W4245135890 hasVolume "37" @default.
• W4245135890 isParatext "false" @default.
• W4245135890 isRetracted "false" @default.
• W4245135890 workType "article" @default.